ALK and non-small cell lung carcinoma: As per recent reports, alectinib significantly delayed CNS progression versus crizotinib [31] and is also a preferred first-line treatment with advanced ALK-positive NSCLC that is approved for the treatment of patients who are intolerant to crizotinib [32].